Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹Zr-Trastuzumab in Patients with Esophagogastric Cancer.

ABSTRACT: Trastuzumab with chemotherapy improves clinical outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive esophagogastric adenocarcinoma (EGA). Despite the therapeutic benefit, responses are rarely complete, and most patients develop progression. To our knowledge, this is the first report evaluating ⁸⁹Zr-trastuzumab in HER2-positive EGA; here, we evaluate the safety, pharmacokinetics, biodistribution, and dosimetry ⁸⁹Zr-trastuzumab. Methods: Trastuzumab was conjugated with deferoxamine and radiolabeled with ⁸⁹Zr. A mean activity of 184 MBq was administered to 10 patients with metastatic HER2-positive EGA. PET imaging, whole-body probe counts, and blood draws were performed to assess pharmacokinetics, biodistribution, and dosi

SUBMITTER: O'Donoghue JA 

PROVIDER: S-EPMC5750520 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature